ArticleVaccine2025
Advancing typhoid conjugate vaccine implementation in Asia: Regional policy priorities.
Article in Vaccine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Typhoid fever, a type of enteric fever transmitted through consumption of food or water contaminated with Salmonella enterica subspecies Typhi, continues to cause illness in Asia. Since the World Health Organization recommended use of typhoid conjugate vaccines in 2018, several countries have introduced or begun the decision-making process to use the vaccine in campaigns or by introduction into the routine immunization schedule. This paper describes the disease burden and vaccine implementation policy setting in the region, based on presentations and discussions at the second Asia Regional Meeting on Typhoid & TCV. Moving forward, typhoid control efforts must prioritize 1) working across health and finance ministries to finance vaccination programs, 2) strengthening surveillance to better understand disease burden, drug resistance trends, and vaccine impact, 3) developing improved diagnostic tests, 4) stewarding antimicrobial use to slow the spread of drug resistance, and 5) evaluating the durability of TCV protection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.